Evommune, Inc.
EVMN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EVMN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with lead candidates EVO756 and EVO301 targeting conditions such as chronic spontaneous urticaria, atopic dermatitis, migraine, and ulcerative colitis.
Key risk: No revenue and ongoing losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials for Evommune, Inc..
Evommune, Inc. is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with lead candidates EVO756 and EVO301 targeting conditions such as chronic spontaneous urticaria, atopic dermatitis, migraine, and ulcerative colitis.
- Clinical-stage company focused on chronic inflammatory diseases, with initial programs in CSU, AD, migraine, and UC [sec_mda · as of 2026-05-07].
- Lead product candidates are EVO756 and EVO301 [sec_mda · as of 2026-08-06].
- Cash & equivalents of $61.2M as of 2026-06-30 [sec].
- Net loss of -$32.2M for the period ended 2026-06-30 [sec].
- Shareholders' equity of -$171.2M as of 2026-06-30 [sec].
What works
- Cash runway expected through 2028 based on $216.7M in cash, equivalents, and investments as of 2026-03-05 [sec_mda · as of 2026-03-05].
- Portfolio targets key drivers of chronic inflammation, addressing large markets like CSU, AD, migraine, and UC [sec_mda · as of 2026-05-07].
What to weigh
- No revenue generated; net loss of -$32.2M for the period ended 2026-06-30 [sec].
- Negative shareholders' equity of -$171.2M as of 2026-06-30 [sec].
- Expects to continue incurring significant and increasing net operating losses for several years [sec_mda · as of 2026-08-06].
- Will need substantial additional funding to maintain operations and advance development [sec_mda · as of 2026-03-05].
From the filings
Quoted directly from source documents.
Company is clinical-stage and focuses on chronic inflammatory diseases.
“clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases”
SEC MD&A · May 7, 2026
Lead candidates are EVO756 and EVO301.
“our most advanced product candidates, EVO756 and EVO301”
SEC MD&A · August 6, 2026
Cash runway expected through 2028.
“we expect that our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements through 2028”
SEC MD&A · March 5, 2026
Company expects continued net operating losses.
“We expect to continue to incur significant and increasing net operating losses for the next several years”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- No revenue and ongoing losses — No revenue generated; net loss of -$32.2M as of 2026-06-30 [sec].
- Need for additional funding — Will need substantial additional funding to maintain operations and advance development [sec_mda · as of 2026-03-05].
- Negative shareholders' equity — Shareholders' equity of -$171.2M as of 2026-06-30 [sec].
- Clinical development risks — Development of product candidates is time-consuming, capital-intensive, and uncertain [sec_mda · as of 2026-03-05].
What to watch
- Progress of clinical trials for EVO756 and EVO301 [sec_mda · as of 2026-08-06].
- Cash burn rate and any future financing events [sec_mda · as of 2026-03-05].
- Regulatory milestones and updates on development timelines [sec_mda · as of 2026-03-05].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Evommune, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Evommune, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
28.9 months
D/E 0.09 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
2 buys · 9 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$751.9M
| Holder | Shares | Value |
|---|---|---|
| eqt fund management s.a r.l. | 4,929,633 | $113.3M |
| ra capital management, l.p. | 3,494,638 | $80.3M |
| pivotal bioventure partners investment advisor llc | 1,926,943 | $44.3M |
| andera partners | 1,897,362 | $43.6M |
| janus henderson group plc | 1,793,400 | $41.2M |
| rtw investments, lp | 1,502,235 | $34.5M |
| mpm bioimpact llc | 1,455,863 | $33.5M |
| nan fung group holdings ltd | 1,441,032 | $33.1M |
| eventide asset management, llc | 1,209,129 | $27.8M |
| vanguard capital management llc | 910,102 | $20.9M |
Showing top 10 of 82 institutional holders of Evommune, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 14.3%
- Days to cover
- 10.1
- Shares short
- 3,459,513
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EVMN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Evommune, Inc.?
Evommune, Inc. is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with lead candidates EVO756 and EVO301 targeting conditions such as chronic spontaneous urticaria, atopic dermatitis, migraine, and ulcerative colitis.
What is Evommune, Inc.'s lead drug candidate?
Evommune, Inc.'s most advanced tracked candidate is evo301 (Phase 2) for Atopic Dermatitis (AD).
Who is the CEO of Evommune, Inc.?
Mr. Luis C. Pena is the chief executive officer of Evommune, Inc. (EVMN).
Where is Evommune, Inc. headquartered?
Evommune, Inc. (EVMN) is headquartered in Palo Alto, CA, United States.
What therapeutic areas does Evommune, Inc. focus on?
Evommune, Inc. develops therapies across Neurology, Immunology, Pain, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.